Previous 10 | Next 10 |
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of fiscal year 2021 before the market ope...
The following slide deck was published by AngioDynamics, Inc. in conjunction with this event. For further details see: AngioDynamics (ANGO) Presents At Canaccord Genuity Virtual MedTech & Diagnostics Forum
Raymond James analyst Jayson Bedford upgraded AngioDynamics ([[ANGO]] +10.8%) to Strong Buy from Market Perform; PT, $18.Analyst says the company offers the most compelling risk/reward in his small cap medical technology coverage. The company's business is still overly diversified, but t...
Represents Largest Catheter Based Thromboaspiration Study Completed to Date AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced the safety and effic...
Declines in procedure counts have increased the pressures on AngioDynamics' business, but weak core growth is a long-standing issue, as is weak margin leverage. Growth drivers like AngioVac, Auryon, and NanoKnife (further down the road), could still ultimately drive better revenue gro...
AngioDynamics, Inc. (ANGO) Q1 2021 Results Conference Call September 29, 2020 08:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - EVP and CFO Conference Call Participants Matthew Mishan - KeyBanc Capital Markets Jayson Bedford - Raymond James Cecilia Furlong - ...
Image source: The Motley Fool. AngioDynamics Inc (NASDAQ: ANGO) Q1 2021 Earnings Call Sep 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: AngioDynamics Inc (ANGO) Q1 2021 Earnings Call Transcript
The following slide deck was published by AngioDynamics, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: AngioDynamics, Inc. 2021 Q1 - Results - Earnings Call Presentation
Gainers: Adial Pharmaceuticals (ADIL) +33%, Spero Therapeutics (SPRO) +16%, LogicBio Therapeutics (LOGC) +14%, AngioDynamics (ANGO) +14%, Windtree Therapeutics (WINT) +10%.Losers: Myovant Sciences (MYOV) -21%, TransMedics Group (TMDX...
Every story has winners and losers. Although there will be no tech winners in this week’s storyline, there are other industries which have benefited from the pandemic. Moreover, there is always space for surprises. On September 28, Cal-Maine Foods (NASDAQ:CALM) reported its first...
News, Short Squeeze, Breakout and More Instantly...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is schedule...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...